Government-Owned Inventions; Availability for Licensing, 14141-14142 [E9-6936]

Download as PDF Federal Register / Vol. 74, No. 59 / Monday, March 30, 2009 / Notices 5. AM Klutz, ZG Gao, J Lloyd, A Shainberg, KA Jacobson. Enhanced A3 adenosine receptor selectivity of multivalent nucleoside-dendrimer conjugates. J Nanobiotechnol. 2008 Oct 23;6:12. Patent Status • U.S. Provisional Application No. 60/947,121 filed 20 Jun 2007 (HHS Reference No. E–219–2007/0–US–01). • U.S. Provisional Application No. 61/045,498 filed 16 Apr 2008 (HHS Reference No. E–219–2007/1–US–01). • International Application No. PCT/ US08/067683 filed 20 Jun 2008, which published as WO2009/006046 on 08 Jan 2009 (HHS Reference No. E–219–2007/ 2–PCT–01). • U.S. Patent Application No.12/ 143,451 filed 20 Jun 2008, which published as U.S. 20090012035 on 08 Jan 2009 (HHS Reference No. E–219– 2007/2–US–02). Licensing Status: Available for licensing. Licensing Contact: Cristina Thalhammer-Reyero, PhD, MBA; 301– 435–4507; thalhamc@mail.nih.gov. Collaborative Research Opportunity: The Laboratory of Bioorganic Chemistry of the National Institute of Diabetes & Digestive & Kidney Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize dendrimer conjugates of suitably functionalized small molecule ligands of adenosine receptors and P2Y nucleotide receptors. Please contact Dr. Kenneth A. Jacobson at 301–496–9024, or e-mail kajacobs@helix.nih.gov, for more information. Dated: March 19, 2009. Richard U. Rodriguez, Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health. [FR Doc. E9–6935 Filed 3–27–09; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health sroberts on PROD1PC70 with NOTICES Government-Owned Inventions; Availability for Licensing AGENCY: National Institutes of Health, Public Health Service, HHS. ACTION: Notice. SUMMARY: The inventions listed below are owned by an agency of the U.S. Government and are available for licensing in the U.S. in accordance with 35 U.S.C. 207 to achieve expeditious VerDate Nov<24>2008 18:33 Mar 27, 2009 Jkt 217001 commercialization of results of Federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing. ADDRESSES: Licensing information and copies of the U.S. patent applications listed below may be obtained by writing to the indicated licensing contact at the Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852–3804; telephone: 301/ 496–7057; fax: 301/402–0220. A signed Confidential Disclosure Agreement will be required to receive copies of the patent applications. M2e Peptide Vaccine Against Influenza Virus Description of Technology: The invention offered here is a vaccine candidate that can potentially confer protection against many types of influenza. Current vaccines against influenza virus are comprised of inactivated virus or purified influenza virus proteins and are targeted primarily to induce neutralizing antibodies against the viral hemagglutinin (HA) protein. The virus can mutate or shift antigenic types of HA rapidly rendering the vaccines ineffective and thus the vaccine has to be evaluated yearly to predict next year’s circulating strains for vaccine preparation. Unlike HA, the small M2 protein is highly conserved among different strains of influenza virus and thus vaccines based on the M2 protein have the potential to be effective against different strains of influenza. The current invention relates to peptide vaccines composed of the extracellular domain of the M2 protein (M2e) conjugated to a carrier protein. In animals studies a mutant diphtheria toxin-M2e—conjugate induced high antibody levels to both vaccine components in mice. Applications: • Preventative and therapeutic for influenza virus. • Vaccine against seasonal and pandemic influenza virus strains. Advantages: Novel vaccine candidate with potential heterosubtypic protection. Development Status: In vitro and in vivo data can be provided upon request. Market: Influenza virus vaccines. Inventors: Mark A. Miller (FIC), Rachel Schneerson (NICHD), Joanna Kubler-Kielb (NICHD), John B. Robbins (NICHD), Zuzanna Biesova (NICHD), and Jerry Keith (NICHD). Patent Status: U.S. Provisional Application No. 61/089,384 filed 15 PO 00000 Frm 00037 Fmt 4703 Sfmt 4703 14141 Aug 2008 (HHS Reference No. E–304– 2008/0–US–01). Licensing Status: Available for licensing. Licensing Contact: Kevin W. Chang, Ph.D.; 301–435–5018; changke@mail.nih.gov. Therapeutic HIV Vaccine and Associated Protocols Description of Technology: This technology describes a therapeutic HIV DNA vaccine to be administered to individuals who have previously experienced or are undergoing antiretroviral therapy (ART). The therapeutic DNA vaccine can also be administered in combination with a vector encoding an IL–15 and/or IL–15 receptor alpha (IL–15Ra) polypeptide. In primate studies, the technology was found to be particularly effective when the vaccine composition was administered by electroporation and expressed six (6) HIV antigens (including two (2) gag polypeptides and two (2) envelope polypeptides) and IL– 15 and IL–15Ra. The antigens are typically modified with a destabilizing sequence, a secretory polypeptide and/ or a degradation signal. Successive administration up to as many as nine resulted in continual boost of the immune response against the encoded antigen. A potent immunotherapeutic vaccine as described here could be an important technology for the fight against HIV/AIDS. Applications: Therapeutic HIV DNA vaccines. Development Status: Primate data available. Inventor: Barbara Felber et al. (NCI). Patent Status: PCT Application No. PCT/US2008/ 51004 filed 14 Jan 2008, which published as WO 2008/089144 on 24 Jul 2008 (HHS Reference No. E–103–2007/ 0–PCT–02); claiming priority to 12 Jan 2007. PCT Application No. PCT/US2007/ 000774 filed 12 Jan 2007, which published as WO 2007/084342 on 26 Jul 2007 (HHS Reference No. E–254–2005/ 2–PCT–01); claiming priority to 13 Jan 2006. National Stage filed in AU, BR, CA, CN, EP, IL, IN, JP, MX, NZ, and US. PCT Application No. PCT/US2001/ 45624 filed 01 Nov 2001, which published as WO 2002/36806 on 10 May 2002 (HHS Reference No. E–308–2000/ 0–PCT–02); claiming priority to 01 Nov 2000. National Stage filed in AU, CA, EP, JP, and US. U.S. Patent Application No. 11/ 571,879 filed 09 Jan 2007 (HHS Reference No. E–249–2004/1–US–02). Licensing Status: Available for licensing. E:\FR\FM\30MRN1.SGM 30MRN1 14142 Federal Register / Vol. 74, No. 59 / Monday, March 30, 2009 / Notices Licensing Contact: Kevin W. Chang, Ph.D.; 301–435–5018; changke@mail.nih.gov. Collaborative Research Opportunity: The National Cancer Institute is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize HIV DNA vaccines. Please contact John D. Hewes, Ph.D. at 301–435–3121 or hewesj@mail.nih.gov for more information. Dated: March 19, 2009. Richard U. Rodriguez, Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health. [FR Doc. E9–6936 Filed 3–27–09; 8:45 am] Hazardous Substances—Basic Research and Education; 93.894, Resources and Manpower Development in the Environmental Health Sciences; 93.113, Biological Response to Environmental Health Hazards; 93.114, Applied Toxicological Research and Testing, National Institutes of Health, HHS) Dated: March 23, 2009. Jennifer Spaeth, Director, Office of Federal Advisory Committee Policy. [FR Doc. E9–6930 Filed 3–27–09; 8:45 am] BILLING CODE 4140–01–P Center for Substance Abuse Prevention; Notice of Meeting National Institutes of Health Pursuant to Public Law 92–463, notice is hereby given that the Substance Abuse and Mental Health Services Administration’s (SAMHSA) Center for Substance Abuse Prevention (CSAP) National Advisory Council will meet on April 30, 2009 from 1 p.m. to 3 p.m. via teleconference. The meeting will include discussion and evaluation of grant applications reviewed by Initial Review Groups. Therefore, the meeting will be closed to the public as determined by the Acting Administrator, SAMHSA, in accordance with Title 5 U.S.C. 552b(c)(6) and 5 U.S.C. App. 2, Section 10(d). Substantive program information, a summary of the meeting, and a roster of Council members may be obtained either by accessing the SAMHSA Committee’s Web site at https:// nac.samhsa.gov/CSAPcouncil/ index.aspx as soon as possible after the meeting, or by contacting CSAP National Advisory Council’s Designated Federal Official, Ms. Tia Haynes (see contact information below). sroberts on PROD1PC70 with NOTICES Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute of Environmental Health Sciences Special Emphasis Panel; NIH Loan Repayment Program Regarding Clinical & Pediatric Researchers. Date: April 29, 2009. Time: 2 p.m. to 5 p.m. Agenda: To review and evaluate grant applications. Place: NIEHS/Keystone Bldg., Keystone Building, 530 Davis Drive, Research Triangle Park, NC 27709. Contact Person: RoseAnne M McGee, Associate Scientific Review Administrator, Scientific Review Branch, Division of Extramural Research and Training, Nat. Institute of Environmental Health Sciences, P.O. Box 12233, MD EC–30, Research Triangle Park, NC 27709. (919) 541–0752. mcgee1@niehs.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.115, Biometry and Risk Estimation—Health Risks from Environmental Exposures; 93.142, NIEHS Hazardous Waste Worker Health and Safety Training; 93.143, NIEHS Superfund VerDate Nov<24>2008 18:33 Mar 27, 2009 Jkt 217001 BILLING CODE 4162–20–P DEPARTMENT OF HOMELAND SECURITY [Docket No. USCG–2009–0192] DEPARTMENT OF HEALTH AND HUMAN SERVICES DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institute of Environmental Health Sciences; Notice of Closed Meeting Toian Vaughn, Committee Management Officer, Substance Abuse and Mental Health, Services Administration. [FR Doc. E9–6960 Filed 3–27–09; 8:45 am] Coast Guard Substance Abuse and Mental Health Services Administration BILLING CODE 4140–01–P 2436; FAX: (240) 276–2430, E-mail: tia.haynes@samhsa.hhs.gov. Committee Name: Substance Abuse and Mental Health Services Administration, Center for Substance Abuse Prevention National Advisory Council. Date/Time/Type: April 30, 2009, 1 p.m. to 3 p.m.: CLOSED. Place: 1 Choke Cherry Road, Conference Room 4–1058, Rockville, Maryland 20857. Contact: Tia Haynes, Designated Federal Official, SAMHSA/CSAP National Advisory Council, 1 Choke Cherry Road, Room 4–1066, Rockville, MD 20857, Telephone: (240) 276– PO 00000 Frm 00038 Fmt 4703 Sfmt 4703 Prince William Sound Regional Citizens’ Advisory Council (PWSRCAC) Charter Renewal Coast Guard, DHS. Notice of recertification. AGENCY: ACTION: SUMMARY: The purpose of this notice is to inform the public that the Coast Guard has recertified the Prince William Sound Regional Citizens’ Advisory Council (PWSRCAC) as an alternative voluntary advisory group for Prince William Sound, Alaska. This certification allows the PWSRCAC to monitor the activities of terminal facilities and crude oil tankers under the Prince William Sound Program established by statute. DATES: This recertification is effective for the period from February 28, 2009, through February 28, 2010. FOR FURTHER INFORMATION CONTACT: LCDR Gary Koehler, Seventeenth Coast Guard District, by telephone at (907) 463–2809, or by mail at 709 W. Ninth Street, Juneau, Alaska 99801. SUPPLEMENTARY INFORMATION: Background and Purpose As part of the Oil Pollution Act of 1990 (OPA 90), Congress passed the Oil Terminal and Oil Tanker Environmental Oversight and Monitoring Act of 1990 (the Act), 33 U.S.C. 2732, to foster a long-term partnership among industry, government, and local communities in overseeing compliance with environmental concerns in the operation of crude oil terminals and oil tankers. On October 18, 1991, the President delegated his authority under 33 U.S.C 2732(o) to the Secretary of Transportation in Executive Order 12777, section 8(g) (see 56 FR 54757; Oct. 22, 1991), for purposes of certifying advisory councils, or groups, subject to the Act. On March 3, 1992, the Secretary redelegated that authority to the Commandant of the Coast Guard (see 57 FR 8582; Mar. 11, 1992). The E:\FR\FM\30MRN1.SGM 30MRN1

Agencies

[Federal Register Volume 74, Number 59 (Monday, March 30, 2009)]
[Notices]
[Pages 14141-14142]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E9-6936]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, Public Health Service, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The inventions listed below are owned by an agency of the U.S. 
Government and are available for licensing in the U.S. in accordance 
with 35 U.S.C. 207 to achieve expeditious commercialization of results 
of Federally-funded research and development. Foreign patent 
applications are filed on selected inventions to extend market coverage 
for companies and may also be available for licensing.

ADDRESSES: Licensing information and copies of the U.S. patent 
applications listed below may be obtained by writing to the indicated 
licensing contact at the Office of Technology Transfer, National 
Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, 
Maryland 20852-3804; telephone: 301/496-7057; fax: 301/402-0220. A 
signed Confidential Disclosure Agreement will be required to receive 
copies of the patent applications.

M2e Peptide Vaccine Against Influenza Virus

    Description of Technology: The invention offered here is a vaccine 
candidate that can potentially confer protection against many types of 
influenza. Current vaccines against influenza virus are comprised of 
inactivated virus or purified influenza virus proteins and are targeted 
primarily to induce neutralizing antibodies against the viral 
hemagglutinin (HA) protein. The virus can mutate or shift antigenic 
types of HA rapidly rendering the vaccines ineffective and thus the 
vaccine has to be evaluated yearly to predict next year's circulating 
strains for vaccine preparation. Unlike HA, the small M2 protein is 
highly conserved among different strains of influenza virus and thus 
vaccines based on the M2 protein have the potential to be effective 
against different strains of influenza. The current invention relates 
to peptide vaccines composed of the extracellular domain of the M2 
protein (M2e) conjugated to a carrier protein. In animals studies a 
mutant diphtheria toxin-M2e--conjugate induced high antibody levels to 
both vaccine components in mice.
    Applications:
     Preventative and therapeutic for influenza virus.
     Vaccine against seasonal and pandemic influenza virus 
strains.
    Advantages: Novel vaccine candidate with potential heterosubtypic 
protection.
    Development Status: In vitro and in vivo data can be provided upon 
request.
    Market: Influenza virus vaccines.
    Inventors: Mark A. Miller (FIC), Rachel Schneerson (NICHD), Joanna 
Kubler-Kielb (NICHD), John B. Robbins (NICHD), Zuzanna Biesova (NICHD), 
and Jerry Keith (NICHD).
    Patent Status: U.S. Provisional Application No. 61/089,384 filed 15 
Aug 2008 (HHS Reference No. E-304-2008/0-US-01).
    Licensing Status: Available for licensing.
    Licensing Contact: Kevin W. Chang, Ph.D.; 301-435-5018; 
changke@mail.nih.gov.

Therapeutic HIV Vaccine and Associated Protocols

    Description of Technology: This technology describes a therapeutic 
HIV DNA vaccine to be administered to individuals who have previously 
experienced or are undergoing antiretroviral therapy (ART). The 
therapeutic DNA vaccine can also be administered in combination with a 
vector encoding an IL-15 and/or IL-15 receptor alpha (IL-15Ra) 
polypeptide. In primate studies, the technology was found to be 
particularly effective when the vaccine composition was administered by 
electroporation and expressed six (6) HIV antigens (including two (2) 
gag polypeptides and two (2) envelope polypeptides) and IL-15 and IL-
15Ra. The antigens are typically modified with a destabilizing 
sequence, a secretory polypeptide and/or a degradation signal. 
Successive administration up to as many as nine resulted in continual 
boost of the immune response against the encoded antigen. A potent 
immunotherapeutic vaccine as described here could be an important 
technology for the fight against HIV/AIDS.
    Applications: Therapeutic HIV DNA vaccines.
    Development Status: Primate data available.
    Inventor: Barbara Felber et al. (NCI).
    Patent Status:
    PCT Application No. PCT/US2008/51004 filed 14 Jan 2008, which 
published as WO 2008/089144 on 24 Jul 2008 (HHS Reference No. E-103-
2007/0-PCT-02); claiming priority to 12 Jan 2007.
    PCT Application No. PCT/US2007/000774 filed 12 Jan 2007, which 
published as WO 2007/084342 on 26 Jul 2007 (HHS Reference No. E-254-
2005/2-PCT-01); claiming priority to 13 Jan 2006. National Stage filed 
in AU, BR, CA, CN, EP, IL, IN, JP, MX, NZ, and US.
    PCT Application No. PCT/US2001/45624 filed 01 Nov 2001, which 
published as WO 2002/36806 on 10 May 2002 (HHS Reference No. E-308-
2000/0-PCT-02); claiming priority to 01 Nov 2000. National Stage filed 
in AU, CA, EP, JP, and US.
    U.S. Patent Application No. 11/571,879 filed 09 Jan 2007 (HHS 
Reference No. E-249-2004/1-US-02).
    Licensing Status: Available for licensing.

[[Page 14142]]

    Licensing Contact: Kevin W. Chang, Ph.D.; 301-435-5018; 
changke@mail.nih.gov.
    Collaborative Research Opportunity: The National Cancer Institute 
is seeking statements of capability or interest from parties interested 
in collaborative research to further develop, evaluate, or 
commercialize HIV DNA vaccines. Please contact John D. Hewes, Ph.D. at 
301-435-3121 or hewesj@mail.nih.gov for more information.

     Dated: March 19, 2009.
 Richard U. Rodriguez,
 Director, Division of Technology Development and Transfer, Office of 
Technology Transfer, National Institutes of Health.
[FR Doc. E9-6936 Filed 3-27-09; 8:45 am]
BILLING CODE 4140-01-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.